Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: AMRN stock price vs STX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at STX's multiple
Needs STX P/S.
Implied fair value · at AMRN's multiple
Needs AMRN P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · STX FY 2026 (ended Jul 3, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AMARIN CORP PLC\UK · implied price per share
Bear
-$0.42
Base
-$0.49
Bull
-$0.56
Seagate Technology Holdings plc · implied price per share
Bear
$141.62
Base
$166.61
Bull
$191.60
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.22x
1.65x
Net debt / EBITDA
Leverage against operating earnings
6.57x
0.18x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$2.72B
Total debt
Interest-bearing obligations outstanding
$99.83M
$3.57B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
WESTERN DIGITAL CORP
AMRN vs WDC
NetApp, Inc.
AMRN vs NTAP
Dell Technologies Inc.
AMRN vs DELL
Hewlett Packard Enterprise Co
AMRN vs HPE
QUANTUM CORP /DE/
AMRN vs QMCO
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe AMRN can reverse revenue declines and convert its high gross margin into sustained positive operating margins, then hold or add selectively because the stock is only modestly within its historical range; otherwise, STX's superior growth and profitability argue that AMRN remains overvalued versus STX-implied case.
AMRN's current price of $15.24 sits above STX-implied price of $11.81, implying 22.5% downside on the P/S framework. The stock is also above STX-implied range and only modestly within its own historical band, which suggests valuation is not yet compelling relative to STX.
Supporting Metrics
